Abogen licenses mRNA T-cell engager to Novartis for $575M upfront

Abogen Biosciences said on October 2, 2026 that it entered a licensing and option agreement with Novartis giving the drugmaker exclusive worldwide rights to ABO2203, an mRNA-encoded CD19xCD3 T-cell engager for autoimmune disease, for $575 million upfront and up to about $7.2 billion in milestones if all options are exercised — with the deal still subject to customary closing conditions and regulatory clearances.

Abogen Biosciences said it has struck a licensing and option deal with Novartis that hands the Swiss drugmaker worldwide rights to ABO2203, an mRNA-encoded T-cell engager aimed at autoimmune disease, for $575 million upfront and as much as about $7.2 billion more in milestones if every option is exercised.

What Abogen disclosed October 2

In a company release dated October 2, 2026, Abogen said it entered into a licensing and option agreement with Novartis covering RNA-encoded therapeutics. The package includes an exclusive worldwide license to ABO2203, described as Abogen’s lead mRNA-encoded CD19xCD3 T-cell engager for autoimmune diseases, plus exclusive options for Novartis to license other potential programs built on Abogen’s RNA platform.

Under the terms of the proposed agreement, Abogen is to receive an upfront payment of $575 million. If all options on all programs are exercised, Abogen said it is eligible for up to approximately $7.2 billion in potential development, regulatory, and commercial milestone payments, and it may also receive royalties on future product sales. Those two disclosed pools are the hard economics in the release; media headlines that round the package to about $7.8 billion are simply adding the upfront and the ceiling milestones.

What ABO2203 is supposed to do

Abogen describes ABO2203 as designed to reset B cells by using mRNA to drive in vivo production of T-cell engagers, a mechanism it casts as distinct from traditional recombinant T-cell engagers. CEO Bo Ying called the pact a milestone for taking Abogen’s RNA platform beyond prophylactic vaccines and said ABO2203 is the first mRNA-encoded T-cell engager to enter clinical evaluation for autoimmune diseases. Fiona Marshall, president of biomedical research at Novartis, said in the same Abogen release that mRNA-encoded T-cell engagers could complement existing modalities by enabling in vivo production of those molecules.

Agreement, not a close

Abogen’s own release frames the economics as terms of a proposed agreement and states that the transaction is subject to customary closing conditions, including required regulatory clearances. This story is an announced licensing-and-option package — not a Completes filing and not evidence that the deal has already closed or that clearances are in hand. Novartis had not posted a matching media release on its public newsroom at the time this package was sealed; the Novartis quotes above appear inside Abogen’s release.

Treat $575 million as the disclosed upfront and about $7.2 billion as an options-conditioned milestone ceiling — not as cash already paid or as a certainty that every option will be exercised.